We went with the non-ambulant population because the research from Pinto Mariz showed that CD49D was substantially higher in older, non-ambulant boys, and ATL1102 targets CD49D. Also, as a small, scrappy biotech with limited resources, it is important to go after unmet needs with limited competition. And, at least when ANP starting embarking down the DMD path in 2017, there was substantially less competition in the non-ambulant space compared to the ambulant space.
- Forums
- ASX - By Stock
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
We went with the non-ambulant population because the research...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.4¢ |
Change
-0.001(1.18%) |
Mkt cap ! $75.73M |
Open | High | Low | Value | Volume |
8.9¢ | 8.9¢ | 8.2¢ | $63.67K | 761.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 43210 | 8.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 200 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 43210 | 0.083 |
1 | 20000 | 0.082 |
1 | 37037 | 0.081 |
3 | 122502 | 0.080 |
1 | 150000 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 200 | 1 |
0.089 | 105978 | 2 |
0.090 | 50000 | 1 |
0.093 | 157142 | 2 |
0.095 | 300000 | 1 |
Last trade - 15.59pm 07/06/2024 (20 minute delay) ? |
|
|||||
Last
8.4¢ |
  |
Change
-0.001 ( 3.45 %) |
|||
Open | High | Low | Volume | ||
8.9¢ | 8.9¢ | 8.2¢ | 115933 | ||
Last updated 14.43pm 07/06/2024 ? |
Featured News
PER (ASX) Chart |